title: Reversal of hippocampal neuronal maturation by serotonergic antidepressants.
abstract: Serotonergic antidepressant drugs have been commonly used to treat mood and anxiety disorders, and increasing evidence suggests potential use of these drugs beyond current antidepressant therapeutics. Facilitation of adult neurogenesis in the hippocampal dentate gyrus has been suggested to be a candidate mechanism of action of antidepressant drugs, but this mechanism may be only one of the broad effects of antidepressants. Here we show a distinct unique action of the serotonergic antidepressant fluoxetine in transforming the phenotype of mature dentate granule cells. Chronic treatments of adult mice with fluoxetine strongly reduced expression of the mature granule cell marker calbindin. The fluoxetine treatment induced active somatic membrane properties resembling immature granule cells and markedly reduced synaptic facilitation that characterizes the mature dentate-to-CA3 signal transmission. These changes cannot be explained simply by an increase in newly generated immature neurons, but best characterized as "dematuration" of mature granule cells. This granule cell dematuration developed along with increases in the efficacy of serotonin in 5-HT(4) receptor-dependent neuromodulation and was attenuated in mice lacking the 5-HT(4) receptor. Our results suggest that serotonergic antidepressants can reverse the established state of neuronal maturation in the adult hippocampus, and up-regulation of 5-HT(4) receptor-mediated signaling may play a critical role in this distinct action of antidepressants. Such reversal of neuronal maturation could affect proper functioning of the mature hippocampal circuit, but may also cause some beneficial effects by reinstating neuronal functions that are lost during development.
authors.affiliation: Department of Pharmacology, Nippon Medical School, Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan. kkatsu-tky@umin.ac.jp
authors.forename: Katsunori
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Ikeda
authors.forename: Atsushi
authors.initials: A
authors.lastname: Sakai
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Yamasaki
authors.forename: Eisuke
authors.initials: E
authors.lastname: Haneda
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Miyakawa
authors.forename: Hidenori
authors.initials: H
authors.lastname: Suzuki
mesh_terms: D000375:Aging; D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology*; D015415:Biomarkers / Q000378:metabolism; D064026:Calbindins; D015536:Down-Regulation; D005473:Fluoxetine / Q000494:pharmacology*; D006624:Hippocampus / Q000187:drug effects* / Q000254:growth & development* / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D044422:Receptors, Serotonin, 5-HT4 / Q000172:deficiency / Q000378:metabolism; D064030:S100 Calcium Binding Protein G / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D015415:Biomarkers; D064026:Calbindins; D064030:S100 Calcium Binding Protein G; D005473:Fluoxetine; D044422:Receptors, Serotonin, 5-HT4; D012701:Serotonin
references.citation: Brain Res. 2004 Aug 13;1017(1-2):21-31
references.pmid: 15261095
references.citation: J Neurosci. 2009 Apr 15;29(15):5000-8
references.pmid: 19369569
references.citation: Science. 2008 Apr 18;320(5874):385-8
references.pmid: 18420937
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):85-102
references.pmid: 12551730
references.citation: Eur J Neurosci. 2002 Jan;15(2):329-44
references.pmid: 11849299
references.citation: Annu Rev Physiol. 2002;64:355-405
references.pmid: 11826273
references.citation: Neuron. 2001 Jan;29(1):209-16
references.pmid: 11182092
references.citation: Mol Neurobiol. 2009 Feb;39(1):24-36
references.pmid: 19130314
references.citation: J Comp Neurol. 1979 Jun 1;185(3):423-59
references.pmid: 86549
references.citation: Science. 2003 Aug 8;301(5634):805-9
references.pmid: 12907793
references.citation: J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):159-69
references.pmid: 16553536
references.citation: Mol Psychiatry. 2008 Feb;13(2):119-21
references.pmid: 18202694
references.citation: CNS Neurosci Ther. 2008 Summer;14(2):153-64
references.pmid: 18482027
references.citation: Nature. 2004 May 13;429(6988):184-7
references.pmid: 15107864
references.citation: Psychopharmacology (Berl). 2008 Nov;200(4):557-72
references.pmid: 18629477
references.citation: PLoS One. 2009;4(4):e5320
references.pmid: 19399173
references.citation: J Neurosci. 2000 Dec 15;20(24):9104-10
references.pmid: 11124987
references.citation: Eur J Neurosci. 2003 Nov;18(10):2707-12
references.pmid: 14656319
references.citation: J Neurosci. 2007 Oct 3;27(40):10906-11
references.pmid: 17913924
references.citation: Neuroscience. 2007 Jan 5;144(1):110-8
references.pmid: 17055173
references.citation: Brain Res Dev Brain Res. 1996 Oct 23;96(1-2):97-108
references.pmid: 8922672
references.citation: J Neurosci. 2008 Jun 11;28(24):6272-80
references.pmid: 18550770
references.citation: Science. 2007 Aug 10;317(5839):819-23
references.pmid: 17615305
references.citation: J Neurosci. 2008 Feb 6;28(6):1374-84
references.pmid: 18256257
references.citation: J Physiol. 2003 Nov 15;553(Pt 1):37-48
references.pmid: 12963803
references.citation: Mol Psychiatry. 2008 Sep;13(9):858-72
references.pmid: 18332879
references.citation: Mol Cell Neurosci. 2003 Nov;24(3):603-13
references.pmid: 14664811
references.citation: J Comp Neurol. 2008 Aug 1;509(4):372-81
references.pmid: 18512685
references.citation: J Comp Neurol. 2005 Apr 18;484(4):418-39
references.pmid: 15770652
references.citation: Prog Brain Res. 2007;163:601-13
references.pmid: 17765740
references.citation: Mol Cell Neurosci. 2008 Nov;39(3):372-83
references.pmid: 18718867
references.citation: Neurosci Lett. 2009 Feb 20;451(2):148-51
references.pmid: 19135130
references.citation: Neuron. 2007 May 24;54(4):559-66
references.pmid: 17521569
references.citation: J Neurobiol. 2000 Feb 5;42(2):248-57
references.pmid: 10640331
references.citation: Neuropharmacology. 2007 Feb;52(2):552-61
references.pmid: 17049952
references.citation: Life Sci. 2003 May 23;73(1):1-17
references.pmid: 12726882
references.citation: J Comp Neurol. 2001 Jul 9;435(4):406-17
references.pmid: 11406822
references.citation: Neuropsychopharmacology. 2008 Jan;33(2):406-17
references.pmid: 17429410
references.citation: Cell. 2008 Feb 22;132(4):645-60
references.pmid: 18295581
references.citation: Neuron. 2004 Feb 5;41(3):445-54
references.pmid: 14766182
references.citation: Mol Brain. 2008 Sep 10;1:6
references.pmid: 18803808
references.citation: Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10409-14
references.pmid: 9294224
references.citation: J Physiol. 2004 Nov 15;561(Pt 1):27-37
references.pmid: 15358807
references.citation: Neuroscience. 2006 Sep 29;142(1):49-58
references.pmid: 16844311
references.citation: Int J Dev Neurosci. 2007 Aug;25(5):265-74
references.pmid: 17616293
references.citation: Eur J Neurosci. 2006 Aug;24(4):1053-62
references.pmid: 16930432
references.citation: Neuropsychopharmacology. 2008 May;33(6):1312-22
references.pmid: 17609676